Guillaume Butler-Laporte1, Samuel De L'Étoile-Morel2, Matthew P Cheng3, Emily G McDonald4, Todd C Lee5. 1. Division of Infectious Diseases, Department of Medicine, McGill University Health Center, Montréal, Canada. Electronic address: guillaume.butler-laporte@mail.mcgill.ca. 2. Division of Internal Medicine, Department of Medicine, McGill University Health Center, Montréal, Canada. 3. Division of Infectious Diseases, Department of Medicine, McGill University Health Center, Montréal, Canada. 4. Division of Internal Medicine, Department of Medicine, McGill University Health Center, Montréal, Canada; Clinical Practice Assessment Unit, McGill University Health Centre, Montréal, Canada. 5. Division of Infectious Diseases, Department of Medicine, McGill University Health Center, Montréal, Canada; Division of Internal Medicine, Department of Medicine, McGill University Health Center, Montréal, Canada; Clinical Practice Assessment Unit, McGill University Health Centre, Montréal, Canada.
Abstract
BACKGROUND: Vancomycin is often used as empiric therapy for methicillin-resistant Staphylococcus aureus (MRSA), but can be associated with clinically important adverse events including renal failure. MRSA colonization swabs are primarily used for infection control; their use as a diagnostic test to inform the decision to add empiric vancomycin therapy has not been well elucidated. METHODS: We performed a Medline and Embase systematic review for peer-reviewed studies reporting the diagnostic accuracy of using MRSA colonization status to predict MRSA infections. Meta-analysis was performed using Cochrane guidelines. Grey literature was excluded. FINDINGS: 29 studies were included involving 24225 patients. In cases where the pathogen is not known to be S. aureus, specificities were greater than 85% for bacteremia, lower respiratory tract infections, skin and soft tissue infections (SSTI), and all infections pooled together. Sensitivities ranged between 54.0% and 77.5%. In cases where the pathogen is known to be S. aureus, we found studies on bacteremia and SSTI and arrived at pooled estimates of sensitivities ranging between 56.6% and 56.9%, and of specificities greater than 91%. Most importantly, for most infections in settings where the prevalence of MRSA as a causative organism is below 15%, the negative predictive value of a negative MRSA colonization swab exceeds 90%. INTERPRETATIONS: In settings of low-moderate MRSA prevalence, negative MRSA screening swabs may prevent unnecessary vancomycin use. More research is needed to assess if this strategy can mitigate the cost of screening in areas with a low MRSA colonization rate.
BACKGROUND:Vancomycin is often used as empiric therapy for methicillin-resistant Staphylococcus aureus (MRSA), but can be associated with clinically important adverse events including renal failure. MRSA colonization swabs are primarily used for infection control; their use as a diagnostic test to inform the decision to add empiric vancomycin therapy has not been well elucidated. METHODS: We performed a Medline and Embase systematic review for peer-reviewed studies reporting the diagnostic accuracy of using MRSA colonization status to predict MRSA infections. Meta-analysis was performed using Cochrane guidelines. Grey literature was excluded. FINDINGS: 29 studies were included involving 24225 patients. In cases where the pathogen is not known to be S. aureus, specificities were greater than 85% for bacteremia, lower respiratory tract infections, skin and soft tissue infections (SSTI), and all infections pooled together. Sensitivities ranged between 54.0% and 77.5%. In cases where the pathogen is known to be S. aureus, we found studies on bacteremia and SSTI and arrived at pooled estimates of sensitivities ranging between 56.6% and 56.9%, and of specificities greater than 91%. Most importantly, for most infections in settings where the prevalence of MRSA as a causative organism is below 15%, the negative predictive value of a negative MRSA colonization swab exceeds 90%. INTERPRETATIONS: In settings of low-moderate MRSA prevalence, negative MRSA screening swabs may prevent unnecessary vancomycin use. More research is needed to assess if this strategy can mitigate the cost of screening in areas with a low MRSA colonization rate.
Authors: Marta Colaneri; Domenico Di Carlo; Alessandro Amatu; Lea Nadia Marvulli; Marta Corbella; Greta Petazzoni; Patrizia Cambieri; Alba Muzzi; Claudio Bandi; Angela Di Matteo; Paolo Sacchi; Francesco Mojoli; Raffaele Bruno Journal: Antibiotics (Basel) Date: 2022-06-24